Arabic Arabic English English French French German German
dark

Starton Therapeutics Receives Clinical Trial Authorization in Europe to Initiate Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide

Starton Therapeutics Inc. announced that it has received a Clinical Trial Authorization (CTA) in the Netherlands to initiate a Phase 1 study evaluating STAR-LLD bioavailability in human subjects. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Sanofi, Exscientia Expand in AI with Up-to-$5.2B Cancer, Immunology Alliance

Next Post

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Related Posts
Total
0
Share